Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Obesity, Adolescent, Bariatric Surgery Candidate
Interventions: Healthy Lifestyle Behavioral Intervention (MBS -supported intervention); Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 18 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar I Disorder
Interventions: Lithium treatment in combination with a SGA (Second Generation Antipsychotic), Placebo/Adjunctive SGA treatment; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Solid Tumors
Interventions: INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 13 more

Conditions: Schizo Affective Disorder, Schizophrenia
Interventions: L-arginine, Sapropterin Dihydrochloride; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Pediatric Solid Tumors
Interventions: perifosine + temsirolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Counseling, combination NRT; Behavioral · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lung Neoplasms, Esophageal Lesion
Interventions: Olympus VE2 NIR Imaging System, Indocyanine green; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Conditions: Local Anesthetic
Interventions: Ropivacaine, Mepivacaine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mesothelioma, Peritoneal Mesothelioma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIB Breast Cancer AJCC v7
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen Citrate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 10,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1160
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 723 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more

Conditions: Bacterial Infections
Interventions: Cefiderocol/Xeruborbactam; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Rosiglitazone; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 16
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 13 more

Conditions: Weight Gain
Interventions: Control, LCD; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Prostate Cancer
Interventions: MyProstateScore 2.0 Results; Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: B-cell Lymphoma
Interventions: Parsaclisib, Rituximab, Bendamustine, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 9
States / cities: Tucson, Arizona • Indianapolis, Indiana • Las Vegas, Nevada + 4 more

Conditions: Heart Failure
Interventions: Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,614,719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: tanespimycin, docetaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin detemir, Insulin NPH, Diet/exercise; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Stroke
Interventions: Yoga focused on strength, flexibility, and balance; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: Abemaciclib 200 MG, Atezolizumab 1200 MG in 20 ML Injection, Abemaciclib 150 MG; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 1 more

Conditions: Skin Flora Contamination
Interventions: InteguSeal* skin sealant and standard surgical preparation, Standard preoperative skin preparation; Procedure · Other
Lead sponsor: Kimberly-Clark Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Marietta, Georgia

Search by objective public record fields.

Lifestyle Improvement for Teens With Bariatric Surgery

Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

Study of INCB123667 in Subjects With Advanced Solid Tumors

L-arginine Study for Persistent Symptoms of Schizophrenia

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Nicotine Replacement Therapy (NRT) Sampling and Selection to Increase Medication Adherence

Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Ultrasound Guided Supraclavicular Nerve Block

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients

Clinical Utility of MyProstateScore 2.0 P2

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Strength, Flexibility, And Balance Therapy After Stroke

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination